Cardiac Amyloidosis is a rare but serious condition characterized by the abnormal buildup of amyloid proteins in the heart tissue. These proteins, often originating from misfolded antibodies or other precursor proteins, form insoluble fibrils that deposit in the heart, affecting its structure and function. As these deposits accumulate, the heart's ability to pump blood efficiently is compromised, leading to symptoms such as fatigue, shortness of breath, and swelling in the legs. The condition is challenging to diagnose due to its diverse clinical presentation, and early detection is crucial for effective management. Treatment approaches may include addressing the underlying cause, managing symptoms, and, in some cases, organ transplantation. With ongoing research and advancements in diagnostic techniques, there is a growing focus on improving outcomes for individuals affected by Cardiac Amyloidosis.
Title : Pharmacological advancement in pulmonary arterial hypertension treatment - Contribution of treprostinil dry-powder formulation
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Historical evolution from OPCAB to MIDCAB to mini OPCAB surgical technique and results
Federico Benetti, Benetti Foundation, Argentina
Title : Personalized and Precision Medicine (PPM) and PPN-guided cardiology practice as a unique model via translational applications and upgraded business modeling to secure human healthcare, wellness and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibodies with functionality as a new generation of translational tools designed to monitor autoimmune myocarditis at clinical and subclinical stages
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation